Sinopharm Tech Holdings Limited

DB:YB2 Stock Report

Market Cap: €3.2m

Sinopharm Tech Holdings Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure7.1yrs
Board average tenure1.1yrs

Recent management updates

Recent updates

CEO

Sinopharm Tech Holdings has no CEO, or we have no data on them.

Leadership Team

NamePositionTenureCompensationOwnership
Kwai Lan Cheung
Co-Founderno dataHK$20.00kno data
Kam Kin Ho
Group CFO7.1yrsHK$1.47mno data
Shuk Yi Kwok
Director of Group Human Resources & Administration and Executive Directorno dataHK$1.00mno data
Siu Sarah Chan
General Counsel15.4yrsno datano data
Wai Wah Chau
Compliance Officer & Executive Director1.2yrsHK$595.00k0.083%
€ 2.7k
King Him Fung
Director of Group Corporate Strategy & Investor Relationsno datano datano data

7.1yrs

Average Tenure

55.5yo

Average Age

Experienced Management: YB2's management team is seasoned and experienced (7.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kam Kin Ho
Group CFO1.1yrsHK$1.47mno data
Shuk Yi Kwok
Director of Group Human Resources & Administration and Executive Director1.1yrsHK$1.00mno data
Wai Wah Chau
Compliance Officer & Executive Director4yrsHK$595.00k0.083%
€ 2.7k
Pik Lun Heung
Independent Non-Executive Directorless than a yearno datano data
Fai Lau
Independent Non-Executive Director3.8yrsHK$104.00kno data
Yanjie Cheng
Non-Executive Director4.3yrsHK$104.00k0.043%
€ 1.4k
Dong An Hsu
Independent Non-Executive Directorless than a yearno datano data

1.1yrs

Average Tenure

52yo

Average Age

Experienced Board: YB2's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/09 09:44
End of Day Share Price 2023/09/13 00:00
Earnings2023/06/30
Annual Earnings2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sinopharm Tech Holdings Limited is covered by 2 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hoi Yin YipEverbright Securities International (HK) Limited (“EBSIHK”)
Hua HeIndustrial Securities (HK) Financial Holdings